Marc-A. Bärtsch
@marc_a_baertsch
Followers
132
Following
194
Media
7
Statuses
140
Postdoc in multiplex tissue immunology @GarryPNolan lab @Stanford and Hemeonc fellow Heidelberg University Hospital @uniklinik_hd focused on myeloma @HDMyeloma
Joined July 2020
RT @RahulBanerjeeMD: 1/ Another exciting year for myeloma #MMsm research! (IMROZ & BENEFIT last year seem like ages ago. ). I'll miss #ASC….
0
15
0
RT @FrancescoMaura4: Excited to share our work investigating the mutagenic impact of radiotherapy in hematological cancers out today in @BC….
0
11
0
RT @HDMyeloma: @NBahlis @BrunoPaiva_UNAV @TCupedo @haas_lab @marc_a_baertsch @RascheLeo @DanaFarber @Leif_Bergsagel @MarkBustoros See you a….
0
3
0
RT @BloodJournal: Time to progression after a frontline autologous transplant does not predict benefit from salvage autologous transplant.….
0
15
0
RT @BloodJournal: The optimal management of relapsed and/or refractory multiple myeloma in patients who have previously received frontline….
0
12
0
RT @HDMyeloma: 📣 We are excited to announce the 10th Heidelberg Myeloma Workshop. Join us on April 25–26, 2025, as international & local e….
0
16
0
RT @ZhuBokai: Finally online in Nature Communications @NatureComms today: Huge thanks to everyone involved in the….
0
8
0
RT @HiraSMian: Would be interested to know if folks are still doing salvage at all… for me it’s become a rare circumstance of someone havin….
0
2
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: Long-term follow-up of Phase 3 GMMG ReLApsE trial of second ASCT finds median PFS was 20.5 & 19….
0
18
0
RT @HDMyeloma: Now out in @BloodJournal: @marc_a_baertsch et al./#GMMG: After >8 yrs mFU the #GMMG ReLApsE phIII trial shows no significant….
0
10
0
RT @SizunJ: Wanna do same slide spatial multi-omics? Check out our new approach, IN-DEPTH, compatible with multiple spatial proteomics and….
0
10
0
RT @VincentRK: AQUILA trial for high risk smoldering myeloma published in @NEJM today. @thanosdimop . Personally for me, it is a huge mile….
0
95
0
RT @VincentRK: Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24 .@thanosdimop @NEJM . Daratumumab….
0
127
0
The overflow rooms were overflowing! Important contributions from German study groups GMMG and DSMM in NDMM: impressive 100% MRD negativity with Teclistamab based regimens in HD10 presented by @RaabMarc and significant PFS benefit with Isa-VRd induction reported by @EliasKarlMai
1
1
6
RT @naturemethods: The wait is over!! We are thrilled to announce that we have chosen Spatial Proteomics as 2024’s Method of the Year! 🥳. F….
0
298
0
RT @NicoGagelmann: 🎉Finally out and timely for #ASH24 @ASH_hematology🎉. Happy to share our international work suggesting bispecific antibod….
0
19
0
@EliasKarlMai @rajshekharucms @HiraSMian @AaronGoodman33 We did check the one in La Jolla last year at #ASH23 @marc_a_baertsch .😬
0
1
9
RT @RahulBanerjeeMD: 1/ 🚨 Now in @BloodCancerJnl - our multicenter description of IEC-associated enterocolitis as a novel toxicity of CAR-T….
0
44
0
RT @GarryPNolan: I am deeply honored to be named by the Stanford Medicine Alumni Association this year for the “Arthur Kornberg and Paul Be….
0
75
0